MX2017009538A - Antigenos de citomegalovirus y su uso. - Google Patents

Antigenos de citomegalovirus y su uso.

Info

Publication number
MX2017009538A
MX2017009538A MX2017009538A MX2017009538A MX2017009538A MX 2017009538 A MX2017009538 A MX 2017009538A MX 2017009538 A MX2017009538 A MX 2017009538A MX 2017009538 A MX2017009538 A MX 2017009538A MX 2017009538 A MX2017009538 A MX 2017009538A
Authority
MX
Mexico
Prior art keywords
proteins
cytomegalovirus antigens
cytomegalovirus
cmv
complexes
Prior art date
Application number
MX2017009538A
Other languages
English (en)
Inventor
Carfi Andrea
Ciferri Claudio
Xing Yi
Original Assignee
Glaxosmithkline Biologicals Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Biologicals Sa filed Critical Glaxosmithkline Biologicals Sa
Publication of MX2017009538A publication Critical patent/MX2017009538A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/081—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from DNA viruses
    • C07K16/082—Hepadnaviridae, e.g. hepatitis B virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A61K39/25—Varicella-zoster virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/081—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16151—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Esta descripción proporciona proteínas gL de citomegalovirus modificados (CMV) y complejos que comprenden proteínas gL. Las proteínas gL modificadas permanecen intactas y son capaces de formar complejos con otras proteínas de CMV.
MX2017009538A 2015-01-22 2016-01-22 Antigenos de citomegalovirus y su uso. MX2017009538A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP15152221.6A EP3048114A1 (en) 2015-01-22 2015-01-22 Cytomegalovirus antigens and uses thereof
PCT/IB2016/050335 WO2016116904A1 (en) 2015-01-22 2016-01-22 Cytomegalovirus antigens and uses thereof

Publications (1)

Publication Number Publication Date
MX2017009538A true MX2017009538A (es) 2017-11-02

Family

ID=52434568

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017009538A MX2017009538A (es) 2015-01-22 2016-01-22 Antigenos de citomegalovirus y su uso.

Country Status (24)

Country Link
US (2) US10167321B2 (es)
EP (3) EP3048114A1 (es)
JP (1) JP6717836B2 (es)
KR (1) KR20170100039A (es)
CN (1) CN107531761B (es)
AU (2) AU2016210548B2 (es)
BE (1) BE1023087B1 (es)
BR (1) BR112017015567A2 (es)
CA (1) CA2974041C (es)
DK (1) DK3247722T3 (es)
EA (1) EA038250B1 (es)
ES (1) ES2937959T3 (es)
FI (1) FI3247722T3 (es)
HR (1) HRP20230177T1 (es)
HU (1) HUE061175T2 (es)
IL (1) IL253366B (es)
LT (1) LT3247722T (es)
MX (1) MX2017009538A (es)
PL (1) PL3247722T3 (es)
PT (1) PT3247722T (es)
SG (1) SG11201705740UA (es)
SI (1) SI3247722T1 (es)
WO (1) WO2016116904A1 (es)
ZA (1) ZA201704912B (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3351636B1 (en) * 2010-05-14 2020-07-01 Oregon Health & Science University Recombinant hcmv and rhcmv vectors encoding a heterologous antigen isolated from a paramyxoviridae virus and uses thereof
CA2832109C (en) 2011-06-10 2021-07-06 Oregon Health & Science University Cmv glycoproteins and recombinant vectors
US10023626B2 (en) 2013-09-30 2018-07-17 Modernatx, Inc. Polynucleotides encoding immune modulating polypeptides
SG11201700315YA (en) 2014-07-16 2017-02-27 Univ Oregon Health & Science Human cytomegalovirus comprising exogenous antigens
EP3256595A4 (en) 2015-02-10 2018-09-26 Oregon Health & Science University Methods and compositions useful in generating non canonical cd8+ t cell responses
US11364292B2 (en) 2015-07-21 2022-06-21 Modernatx, Inc. CHIKV RNA vaccines
MA42502A (fr) 2015-07-21 2018-05-30 Modernatx Inc Vaccins contre une maladie infectieuse
WO2017070613A1 (en) 2015-10-22 2017-04-27 Modernatx, Inc. Human cytomegalovirus vaccine
EP3364950A4 (en) 2015-10-22 2019-10-23 ModernaTX, Inc. VACCINES AGAINST TROPICAL DISEASES
MA43285A (fr) 2015-11-20 2018-09-26 Univ Oregon Health & Science Vecteurs cmv comprenant des éléments de reconnaissance des microarn
US11318197B2 (en) 2016-03-03 2022-05-03 Duke University Compositions and methods for inducing HIV-1 antibodies
EP3423091A4 (en) 2016-03-03 2019-10-30 Duke University COMPOSITIONS AND METHODS OF INDUCING HIV-1 ANTIBODIES
CA3039089A1 (en) 2016-10-03 2018-04-12 Duke University Methods to identify immunogens by targeting improbable mutations
CA3040303A1 (en) 2016-10-18 2018-04-26 Oregon Health & Science University Cytomegalovirus vectors eliciting t cells restricted by major histocompatibility complex e molecules
AU2017345766A1 (en) 2016-10-21 2019-05-16 Modernatx, Inc. Human cytomegalovirus vaccine
EP3582790A4 (en) 2017-02-16 2020-11-25 ModernaTX, Inc. VERY POWERFUL IMMUNOGENIC COMPOSITIONS
EP3612550A1 (en) * 2017-04-19 2020-02-26 GlaxoSmithKline Biologicals S.A. Modified cytomegalovirus proteins and stabilized complexes
WO2019055807A1 (en) 2017-09-14 2019-03-21 Modernatx, Inc. RNA VACCINES AGAINST ZIKA VIRUS
WO2019070730A1 (en) 2017-10-02 2019-04-11 Duke University MOSAIC ENVELOPES OF HIV-1 TO INDUCE ADCC RESPONSES
EP3758747A1 (en) 2018-02-28 2021-01-06 University of Washington Self-asssembling nanostructure vaccines
JP2022505094A (ja) 2018-10-17 2022-01-14 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 改変されたサイトメガロウイルスタンパク質及び安定化された複合体
CN109627330A (zh) * 2018-12-18 2019-04-16 马鞍山史记动物健康管理有限公司 一种猪伪狂犬病毒高效价阳性血清制备方法
US20230201334A1 (en) 2019-07-24 2023-06-29 Glaxosmithkline Biologicals Sa Modified human cytomegalovirus proteins
US11406703B2 (en) 2020-08-25 2022-08-09 Modernatx, Inc. Human cytomegalovirus vaccine
WO2023144665A1 (en) 2022-01-28 2023-08-03 Glaxosmithkline Biologicals Sa Modified human cytomegalovirus proteins

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5219740A (en) 1987-02-13 1993-06-15 Fred Hutchinson Cancer Research Center Retroviral gene transfer into diploid fibroblasts for gene therapy
WO1991006666A1 (en) 1989-11-06 1991-05-16 Cell Genesys, Inc. Production of proteins using homologous recombination
EP3031469B1 (en) 2006-06-07 2023-08-23 The Trustees Of Princeton University Cytomegalovirus surface protein complex for use in vaccines and as a drug target
DK3009449T3 (en) * 2008-07-16 2018-08-06 Inst Res Biomedicine Human cytomegalovirus neutralizing antibodies and their use
ES2443952T3 (es) 2009-09-02 2014-02-21 Novartis Ag Composiciones inmunógenas que incluyen moduladores de la actividad de TLR
BR112013000391B8 (pt) 2010-07-06 2022-10-04 Novartis Ag Composição de emulsão catiônica de óleo em água e seu uso
JP2013544504A (ja) 2010-10-11 2013-12-19 ノバルティス アーゲー 抗原送達プラットフォーム
US9636410B2 (en) 2011-07-06 2017-05-02 Glaxosmithkline Biologicals Sa Cationic oil-in-water emulsions
TWI570240B (zh) * 2011-09-09 2017-02-11 默沙東公司 作為細胞巨大病毒疫苗之條件式複製ｃｍｖ
JP2015522581A (ja) 2012-07-06 2015-08-06 ノバルティス アーゲー サイトメガロウイルスタンパク質の複合体
ES2608637T3 (es) * 2012-10-30 2017-04-12 Pfizer Inc. Vacunas basadas en partículas recombinantes contra la infección por el citomegalovirus humano
US11242551B2 (en) 2013-12-20 2022-02-08 Novartis Ag Eukaryotic cells and methods for recombinantly expressing a product of interest
SG11201604215XA (en) 2013-12-20 2016-07-28 Novartis Ag Novel eukaryotic cells and methods for recombinantly expressing a product of interest
EP3015475A1 (en) 2014-10-31 2016-05-04 Novartis AG Mammalian cells expressing cytomegalovirus antigens
EP3047856A1 (en) 2015-01-23 2016-07-27 Novartis AG Cmv antigens and uses thereof

Also Published As

Publication number Publication date
CA2974041C (en) 2023-04-04
WO2016116904A1 (en) 2016-07-28
LT3247722T (lt) 2023-02-10
AU2016210548A1 (en) 2017-08-10
HRP20230177T1 (hr) 2023-04-14
HUE061175T2 (hu) 2023-05-28
IL253366B (en) 2022-03-01
JP2018504117A (ja) 2018-02-15
EP3048114A1 (en) 2016-07-27
EA201791562A1 (ru) 2018-04-30
BE1023087A1 (fr) 2016-11-18
US20190276498A1 (en) 2019-09-12
AU2018226521A1 (en) 2018-09-27
BE1023087B1 (fr) 2016-11-18
EP3247722A1 (en) 2017-11-29
US20170369532A1 (en) 2017-12-28
CA2974041A1 (en) 2016-07-28
ZA201704912B (en) 2018-12-19
CN107531761B (zh) 2022-01-14
JP6717836B2 (ja) 2020-07-08
SI3247722T1 (sl) 2023-04-28
KR20170100039A (ko) 2017-09-01
US10167321B2 (en) 2019-01-01
EP4180056A1 (en) 2023-05-17
EA038250B1 (ru) 2021-07-29
SG11201705740UA (en) 2017-08-30
IL253366A0 (en) 2017-09-28
FI3247722T3 (fi) 2023-03-17
DK3247722T3 (da) 2023-01-30
AU2018226521B2 (en) 2019-10-31
BR112017015567A2 (pt) 2018-03-13
AU2016210548B2 (en) 2018-11-08
PT3247722T (pt) 2023-01-31
EP3247722B1 (en) 2022-11-30
CN107531761A (zh) 2018-01-02
ES2937959T3 (es) 2023-04-03
PL3247722T3 (pl) 2023-03-20

Similar Documents

Publication Publication Date Title
MX2017009538A (es) Antigenos de citomegalovirus y su uso.
PH12017502180A1 (en) Tau-binding antibodies
PH12018500711A1 (en) Anti-pd1 antibodies and methods of use
PH12017500022A1 (en) Carrier-antibody compositions and methods of making and using the same
MX2022008781A (es) Anticuerpos que se unen a interleucina 8 (il-8) y sus usos.
PH12017500861A1 (en) Anti-interleukin-33 antibodies and uses thereof
MX2019007021A (es) Anticuerpos il-11ra.
SG10201803042PA (en) Anti-tim-3 antibodies
PH12016501644B1 (en) Binding proteins and methods of use thereof
MY191581A (en) Anti-pd-1 antibodies
MX2019007020A (es) Anticuerpos il-11.
EP4335874A3 (en) Anti-hla-g antibodies and use thereof
PH12017502207A1 (en) Tau-binding antibodies
NZ725568A (en) Modified j-chain
MX2017003478A (es) Anticuerpos anti-fgfr2/3 y metodos para su uso.
FR3021319B1 (fr) Peptides, compositions les comprenant et utilisations notamment cosmetiques
EP3353213A4 (en) NOVEL ANTI-MESOTHELIN ANTIBODY AND COMPOSITION COMPRISING SAME
WO2016061389A3 (en) Anti-alpha-synuclein antibodies and methods of use
EP3283516A4 (en) ANTI-PACAP ANTIBODIES AND USES THEREOF
MY191539A (en) Streptococcal vaccine
EP3137103A4 (en) Methods and compositions for modulating the immune system with arginase i
MX2016004802A (es) Anticuerpos anti-r-espondina (anti-rspo) y metodos de uso.
EP3373941A4 (en) MODIFIED IMMUNOCELLS AND USES THEREOF
IN2014MU01248A (es)
MX2016016233A (es) Anticuerpos anti-lgr5 y sus usos.